**Supporting Statement – Part B**

Collections of Information Employing Statistical Methods

**1. Describe (including a numerical estimate) the potential respondent universe and any sampling or other respondent selection method to be used. Data on the number of entities (e.g., establishments, State and local government units, households, or persons) in the universe covered by the collection and in the corresponding sample are to be provided in tabular form for the universe as a whole and for each of the strata in the proposed sample. Indicate expected response rates for the collection as a whole. If the collection had been conducted previously, include the actual response rate achieved during the last collection.**

The Data Validation Contractor will randomly sample 300 facilities, per contract and Quality Incentive Program (QIP) rule guidelines, for participation in the validation project. As a random sample, this should be a representative sample of all included facilities nationally. The sample pool will consist of Medicare-certified dialysis facilities that are required to submit administrative and clinical data into the End-Stage Renal Disease Quality Reporting System (EQRS), formerly known as CROWNWeb, to meet Section 494.180(h) of the 2008 updated Conditions for Coverage for ESRD Dialysis Facilities.

The selected facilities will be asked to submit records that will be validated for the Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) dialysis event elements. The patient sample size is limited to a total of 20 patients (or the maximum patients possible) per facility across two quarters of the calendar year, as per contract and finalized QIP rule guidelines. The medical records will be for patients with “candidate events” as well as randomly selected patients. Candidate events include positive blood cultures, intravenous antimicrobials, or vascular site infection (e.g. pus, redness, or increased swelling).

Sample Size Estimates

The Data Validation Contractor will segment selected facilities by CMS Network Number and by affiliation with major dialysis organizations (DaVita, DCI, Fresenius, and all others as Independent). Sample size estimates for PY 2026 are shown in **Table 1** and **2**,respectively.

***Table 1: Estimated Sample Distribution of Patients within Network Number***

| **Network Number** | **Patient Population Percentage** |
| --- | --- |
| 1 | 1.7 |
| 2 | 10.7 |
| 3 | 3.7 |
| 4 | 2.7 |
| 5 | 5.0 |
| 6 | 6.3 |
| 7 | 5.3 |
| 8 | 4.0 |
| 9 | 6.7 |
| 10 | 3.0 |
| 11 | 4.3 |
| 12 | 1.0 |
| 13 | 2.0 |
| 14 | 11.7 |
| 15 | 6.3 |
| 16 | 4.0 |
| 17 | 7.7 |
| 18 | 14.0 |
| Total | 100 |

***Table 2: Estimated Sample Distribution of Patients within Affiliation***

| **Affiliation** | **Patient Population Percentage** |
| --- | --- |
| DaVita | 43.0 |
| DCI | 1.7 |
| Fresenius | 42.0 |
| Independent | 13.3 |
| Total | 100 |

In accordance with guidance provided by CDC, each facility should provide the following five lists:

**List 1.** All patients who had one or more in-center hemodialysis treatment(s) during the validation time period;

**List 2.** All patients who had any positive blood cultures during the validation time period;

**List 3.** All patients who received any intravenous antimicrobials during the validation time period;

**List 4.** All patients who had any pus, redness or swelling at the vascular access site during the validation time period; and

**List 5.** All patients who were hospitalized for any reason during the validation time period.

Twenty (20) patient records, from each facility, should be selected to undergo medical record review:

1. Start with List 2 to identify the patient medical records.
   1. If List 2 has greater than 20 patients, randomly select 20 patients and STOP.
   2. If List 2 consists of less than 20 patients, select all the patients in that list and then move forward to List 3, 4 and 5 consecutively and randomly select patients from next list until a total of 20 patients is selected.
2. If Lists 2 - 5 together do not generate 20 patients, randomly select the remaining needed patients from List 1 patients who were not included in Lists 2-5.

Sampling Time Frame

Facilities will be randomly selected from the national collection of ESRD facilities, and will not include those facilities already selected for participation in the Clinical Performance Measures (CPM) component of the validation. Patient records across two quarters of PY 2026 will be used according to the finalized guidelines of the ESRD QIP rule.

A breakdown of the mandated reported deadlines that were taken into consideration is displayed in **Table 3.**

***Table 3: Mandated Reporting Deadlines***

|  |  |
| --- | --- |
| **Submission Type** | **Mandated Reporting Deadlines** |
| PY 2026 NHSN Data Submission | 90 days after quarter close |
| Facility Record Submission Deadline – NHSN | 60 days after request receipt per QIP rule |

Due to the tight timeframe for data abstraction, effective coordination and management as well as adherence to established schedules will be crucial to the project’s success.

**2. Describe the procedures for the collection of information including:**

**- Statistical methodology for stratification and sample selection,**

**- Estimation procedure,**

**- Degree of accuracy needed for the purpose described in the justification,**

**- Unusual problems requiring specialized sampling procedures, and**

**- Any use of periodic (less frequent than annual) data collection cycles to reduce burden.**

Please see response to question 1 for statistical methodology for stratification and sample selection, including estimation procedure and degree of accuracy needed for the purpose of this work. As noted below in response to question 4, there are no unusual problems requiring specialized sampling procedures, as the previous experience on the previous CMS NHSN validation effort has shown near universal compliance by the hospitals with medical record requests. The period for data collection cycles is expected to be no more frequently than annually.

**3. Describe methods to maximize response rates and to deal with issues of non-response. The accuracy and reliability of information collected must be shown to be adequate for intended uses. For collections based on sampling, a special justification must be provided for any collection that will not yield 'reliable' data that can be generalized to the universe studied.**

The Validation Contractor will communicate directly with each facility using the Secure File Option within QualityNet. Request letters, including all instructions on the types of records to be submitted, methods to submit records to the contractor, and identified patients selected for validation, will be sent using this method. If necessary, follow up emails and phone calls will be made.

Data Validation

The main objective of this analysis is to perform a single comparison of the NHSN system against NHSN “candidate event” data obtained from the facilities’ records, leading to an evaluation of the reliability (i.e., the data are reasonably complete and accurate) and validity (i.e., the data actually represent what is being measured) of NHSN data. Candidate events include positive blood cultures, intravenous antimicrobials, or vascular site infection (e.g. pus, redness, or increased swelling).

Reliability: Reliability means data are reasonably complete and accurate, meet intended purposes, and are not subject to inappropriate alteration, where:

* + Completeness refers to the extent that relevant records are present and the fields in each record are populated appropriately; and
  + Accuracy refers to the extent recorded data reflect the actual underlying information. In this instance, that the data in the NHSN system accurately reflects the data contained within the source documents, i.e. the facilities’ medical records.

**Validity:** Validity (as used here) refers to whether the data represent what one believes is being measured. A few measures are commonly used to assess validity of any measure.

In our interpretation of these measures, we identify the key sources of overall disagreement between the NHSN data and the patients’ medical records, which would serve as the “gold standard.” Typical sources of disagreement include missing information about events, inaccurate dates and inaccurate dialysis catheter information.

**4. Describe any tests of procedures or methods to be undertaken. Testing is encouraged as an effective means of refining collections of information to minimize burden and improve utility. Tests must be approved if they call for answers to identical questions from 10 or more respondents. A proposed test or set of tests may be submitted for approval separately or in combination with the main collection of information.**

As noted above, the sample pool will consist of Medicare-certified dialysis facilities that are required to submit administrative and clinical data into EQRS in order to meet Section 494.180(h) of the 2008 updated Conditions for Coverage for ESRD Dialysis Facilities. The previous experience on CMS NHSN validation efforts has shown near universal compliance with medical record requests. No additional tests of procedures or methods to be undertaken are expected.

**5. Provide the name and telephone number of individuals consulted on statistical aspects of the design and the name of the agency unit, contractor(s), grantee(s), or other person(s) who will actually collect and/or analyze the information for the agency.**

Delia Houseal, Centers for Medicare and Medicaid Services, (410) 786-2724